{"id":"W4399437467","doi":"10.1007/s00417-024-06531-9","title":"Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes","year":2024,"lang":"en","type":"review","venue":"Graefe s Archive for Clinical and Experimental Ophthalmology","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche; Roche","keywords":"Aflibercept; Macular degeneration; Medicine; Ranibizumab; Ophthalmology; Pegaptanib; Bevacizumab; Choroidal neovascularization; Placental growth factor; Clinical trial; Diabetic macular edema; Diabetic retinopathy; Macular edema; Vascular endothelial growth factor; Surgery; Internal medicine; VEGF receptors; Retinal; Diabetes mellitus; Chemotherapy; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003842068,0.0007580558,0.003923972,0.0001624105,0.000186913,0.00005232468,0.0001415651,0.000450968,0.00003446334],"category_scores_gemma":[0.000517147,0.0004971647,0.002213035,0.0001044502,0.0005895029,0.0000374885,0.0003575577,0.0003504667,0.0000313904],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005137739,"about_ca_system_score_gemma":0.0000914248,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002106417,"about_ca_topic_score_gemma":4.992581e-7,"domain_scores_codex":[0.9958315,0.0003252928,0.001686933,0.001477,0.0001938929,0.0004853763],"domain_scores_gemma":[0.9973042,0.001583407,0.0002452034,0.0004189563,0.00005798637,0.000390256],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.006060102,0.01147516,0.003343828,0.02712745,0.06081159,0.007004771,0.001117563,0.000001466149,0.00009682475,0.001874349,0.003603477,0.8774834],"study_design_scores_gemma":[0.03644866,0.03511465,0.001723498,0.01299396,0.07400134,0.002059298,0.0004966438,0.0003304006,0.00007542414,0.02351562,0.8107502,0.002490242],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.1074374,0.8854153,0.0000569078,0.0002164428,0.0008046276,0.004672513,0.001327812,0.00004050074,0.00002849018],"genre_scores_gemma":[0.01517438,0.9712012,0.004473788,0.000289827,0.0002833288,0.003289281,0.004601778,0.0001490605,0.0005372997],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8749931,"threshold_uncertainty_score":0.999748,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2337610196381718,"score_gpt":0.5444026712076712,"score_spread":0.3106416515694993,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}